Financings in Brief: T Cell Sciences
This article was originally published in The Gray Sheet
Executive SummaryT Cell Sciences: Raises $6.4 mil. in private placement of 2.55 mil. shares of common stock. "Several institutional investors and private investors" participated in the placement, the firm says. T Cell's diagnostics subsidiary received 510(k) clearance from FDA earlier this year for its TRAx CD4 immunoassay test kit ("The Gray Sheet" May 22, p. 18). However, most of the proceeds from the offering will be put toward advancing the company's complement inhibitor program, T Cell says...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.